{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:41:51Z","timestamp":1778661711909,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.intimp.2013.05.003","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T22:30:56Z","timestamp":1369348256000},"page":"492-497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors"],"prefix":"10.1016","volume":"16","author":[{"given":"Massimo","family":"Tempestilli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gentilotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Nicastri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"De Nardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Narciso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leopoldo P.","family":"Pucillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2013.05.003_bb0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.antiviral.2009.10.018","article-title":"The evolution of HIV treatment guidelines: current state-of-the-art of ART","volume":"85","author":"Zolopa","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.intimp.2013.05.003_bb0010","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3851\/IMP1697","article-title":"In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients","volume":"15","author":"Dierynck","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.intimp.2013.05.003_bb0015","author":"Department of Health and Human Services"},{"key":"10.1016\/j.intimp.2013.05.003_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkn455","article-title":"Eradication of HIV: current challenges and new directions","volume":"63","author":"Marsden","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/156800909788166493","article-title":"Multidrug resistance through the spectacle of P-glycoprotein","volume":"9","author":"Goda","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.intimp.2013.05.003_bb0030","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jac\/dkg137","article-title":"The mechanisms that control intracellular penetration of the HIV protease inhibitors","volume":"51","author":"Hoggard","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0035","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.48.4.1073-1081.2004","article-title":"P glycoprotein in human immunodeficiency virus type 1 infection and therapy","volume":"48","author":"Sankatsing","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00126334-200308150-00001","article-title":"The effects of protease inhibitors and non-nucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro","volume":"33","author":"Chandler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.intimp.2013.05.003_bb0045","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkm353","article-title":"Inhibition of P-glycoprotein and multidrug resistance associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes","volume":"60","author":"Janneh","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0050","first-page":"4","article-title":"HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein","volume":"7","author":"Cianfriglia","year":"2007","journal-title":"Retrovirology"},{"key":"10.1016\/j.intimp.2013.05.003_bb0055","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/AAC.00733-08","article-title":"Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation","volume":"53","author":"Bousquet","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejphar.2007.11.007","article-title":"Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors","volume":"579","author":"Weiss","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.intimp.2013.05.003_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11318110-000000000-00000","article-title":"Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action","volume":"49","author":"Bazzoli","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.intimp.2013.05.003_bb0070","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1021\/mp300512r","article-title":"PXR\/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein","volume":"10","author":"Holmstock","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.intimp.2013.05.003_bb0075","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/bi972709x","article-title":"HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter","volume":"37","author":"Lee","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2013.05.003_bb0080","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jnr.21898","article-title":"Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line","volume":"87","author":"Zastre","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.intimp.2013.05.003_bb0085","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bcp.2007.01.027","article-title":"Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein","volume":"73","author":"Storch","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.intimp.2013.05.003_bb0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0169-409X(02)00171-0","article-title":"Drug-drug interaction mediated by inhibition and induction of P-glycoprotein","volume":"55","author":"Lin","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.intimp.2013.05.003_bb0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.toxlet.2004.12.008","article-title":"Does inhibition of P-glycoprotein lead to drug-drug interactions?","volume":"156","author":"Balayssac","year":"2005","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.intimp.2013.05.003_bb0100","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.drudis.2007.07.022","article-title":"Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I Preclinical aspects","volume":"12","author":"Aszalos","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.intimp.2013.05.003_bb0105","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2174\/138920008786927776","article-title":"Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs","volume":"9","author":"Aszalos","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.intimp.2013.05.003_bb0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1871520610909040415","article-title":"Recent advances in the development of P-gp inhibitors","volume":"9","author":"Baumert","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.intimp.2013.05.003_bb0190","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1093\/jac\/dkq324","article-title":"Impact of drug transporters on cellular resistance towards saquinavir and darunavir","volume":"65","author":"K\u00f6nig","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0120","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1248\/bpb.32.1588","article-title":"P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-ransfected renal LLC-PK1 cell lines","volume":"32","author":"Fujimoto","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.intimp.2013.05.003_bb0125","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dkq501","article-title":"Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro","volume":"66","author":"Zembruski","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.intimp.2013.05.003_bb0130","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1128\/AAC.00623-10","article-title":"Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir","volume":"55","author":"Moss","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0135","first-page":"3010","article-title":"Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations","volume":"56","author":"Beck","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2013.05.003_bb0165","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/jac\/dkq295","article-title":"Efficacy, safety and pharmacokinetics of 900\/100mg of darunavir\/ritonavir once daily in treatment-experienced patients","volume":"65","author":"Curran","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1128\/AAC.00789-10","article-title":"Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800milligrams) in HIV-infected patients","volume":"55","author":"Molt\u00f3","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0022-1759(02)00020-0","article-title":"Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo","volume":"262","author":"Meaden","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.intimp.2013.05.003_bb0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.V93.2.599","article-title":"P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833","volume":"93","author":"Egashira","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2013.05.003_bb0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejps.2006.05.009","article-title":"The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux","volume":"29","author":"Hayeshi","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.intimp.2013.05.003_bb0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00126334-200108010-00001","article-title":"HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART","volume":"27","author":"Lucia","year":"2001","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.intimp.2013.05.003_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00001432-200202000-00002","article-title":"Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules","volume":"15","author":"Hoggard","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.intimp.2013.05.003_bb0175","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jac\/dkf161","article-title":"P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals","volume":"50","author":"Meaden","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.intimp.2013.05.003_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.ajkd.2009.01.268","article-title":"Drug\u2013drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus","volume":"54","author":"Mertz","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.intimp.2013.05.003_bb0185","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/jac\/dkq054","article-title":"Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir","volume":"65","author":"Bickel","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576913001835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576913001835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T02:49:33Z","timestamp":1595818173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576913001835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1567576913001835"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2013.05.003","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2013.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}